52
Growth Score
pts
Heat Score
-38 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
713916
Aisa Pharma develops novel oral treatments like Profervia® for Raynaud's disease and explores new therapeutic applications.
- Andrew Sternlicht: CEO and Founder
About the Company
Aisa Pharma is a clinical-stage biopharmaceutical company focused on developing novel oral treatments. It is currently working on Profervia® for patients with primary and secondary Raynaud's disease. The company explores the potential of calcium channel blockers, traditionally used for high blood pressure, for new therapeutic applications.
Aisa Pharma has initiated Part 2 of the RECONNOITER Phase 2 study and has received an NIH-NINDS award to investigate Profervia® as a non-opioid analgesic for acute and chronic pain. The company's research suggests that Profervia® treatment may also impact the severity of Systemic Sclerosis (SSc).
